Inmune Bio

INMBNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$55.430 M

$2.09 +9.16%

Close of 7 Aug 2026

Revenue

$50.0K

#3629 by revenue

Earnings

-$46.0M

Loss-making

Shares outstanding

27,753,789

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#122Genenta Science S.p.A.GNTA$62.7M
#123ScilexSCLX$59.0M
#124Inmune BioINMB$55.4M
#125MiNK TherapeuticsINKT$54.6M
#126TScan TherapeuticsTCRX$52.0M

Where these numbers come from

Share counts and financials for Inmune Bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.